Opus Genetics, Inc. (IRD)
| Market Cap | 323.63M +369.8% |
| Revenue (ttm) | 9.86M -36.1% |
| Net Income | -107.61M |
| EPS | -1.29 |
| Shares Out | 83.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 466,030 |
| Open | 4.170 |
| Previous Close | 4.110 |
| Day's Range | 3.890 - 4.210 |
| 52-Week Range | 1.170 - 5.810 |
| Beta | 0.58 |
| Analysts | Strong Buy |
| Price Target | 10.61 (+172.75%) |
| Earnings Date | Aug 6, 2026 |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ... [Read more]
Financial Performance
In 2025, Opus Genetics's revenue was $14.20 million, an increase of 29.15% compared to the previous year's $10.99 million. Losses were -$49.59 million, -13.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for IRD stock is "Strong Buy." The 12-month stock price target is $10.61, which is an increase of 172.75% from the latest price.
News
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent bl...
Opus Genetics price target lowered to $9 from $10 at RBC Capital
RBC Capital lowered the firm’s price target on Opus Genetics (IRD) to $9 from $10 and keeps an Outperform rating on the shares.
Opus Genetics Registration statement: Registration filing
Opus Genetics filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Opus Genetics files $300M mixed securities shelf
06:23 EDT Opus Genetics (IRD) files $300M mixed securities shelf
Opus Genetics reports Q2 EPS (14c), consensus (16c)
Reports Q2 revenue $755,000, consensus $2.57M. “With a focus on execution, we are rapidly advancing five gene therapy programs that address significant unmet need in inherited retinal diseases, with O...
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Opus Genetics Earnings release: Q2 2026
Opus Genetics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Opus Genetics Quarterly report: Q2 2026
Opus Genetics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Opus Genetics enrolls last patient in OPGx-LCA5 trial
Opus Genetics (IRD) announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the company’s investigational gene therapy for LCA5-associated ...
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Topline six-month efficacy data expected by end of 2027 Phase 3 study follows FDA alignment on registrational trial design through Rare Disease Evidence Principles (RDEP) program Opus Genetics may sub...
Opus Genetics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Opus Genetics (IRD) with a Buy rating without a price target The company’s adeno-associated virus gene therapies replenish wild-type copies of pathological genes that dr...
Opus Genetics sets September timeline for retinal disease trial data
Opus Genetics (IRD) provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial targeting BEST-1 associated inherited retinal diseases. The company expects to announce three-month topline data...
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene...
Opus Genetics FDA alignment further de-risks path to market, says Chardan
After Opus Genetics (IRD) announced that it has reached alignment with the FDA on the design of its registrational Phase 3 clinical trial evaluating OPGx-LCA5 for LCA5-associated IRD, an early-onset…
Opus Genetics announces FDA alignment on OPGx-LCA5 trial
Opus Genetics (IRD) announced that it has reached alignment with the FDA in a Type B Rare Disease Evidence Principles, or RDEP, meeting on the design of its registrational Phase…
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provide...
Opus Genetics to join Russell 3000, Russell 2000 and Russell Microcap Indexes
Opus Genetics (IRD) announced the company will be added as a member of the broad-market Russell 3000, the Russell 2000 and the Russell Microcap Indexes, effective when the U.S. market…
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapi...
Opus Genetics initiated with an Outperform at RBC Capital
RBC Capital initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target Opus is a gene therapy company focused on inherited retinal disease, notes the analyst,…
Opus Genetics assumed with a Buy at Chardan
Chardan assumed coverage of Opus Genetics (IRD) with a Buy rating and a price target of $13, up from $11. The company’s Virtual R&D Science Forum laid the scientific rationale…
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Rapidly Advancing Five IRD Programs with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2...
Opus Genetics Transcript: R&D Day 2026
A diversified gene therapy pipeline for inherited retinal diseases is advancing, with multiple programs entering or progressing through clinical trials and several readouts expected by 2027. Strong partnerships, regulatory designations, and a solid financial runway support execution, while patient-centric and adaptive strategies address operational challenges.
Opus Genetics Slides: FY 2026
Opus Genetics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 16, 2026.
Opus Genetics management to meet with BTIG
Biotechnology Analyst Shrader holds a meeting with management in San Francisco on June 23 hosted by BTIG.
Opus Genetics registers to sell 2.68M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 2.68M shares of common stock. The company is not selling any…